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Abstract. The pathogenesis of plasma leakage during dengue hemorrhagic fever/dengue shock syndrome (DHF/
DSS) is largely unknown. Angiopoietins are key regulators of vascular integrity: Angiopoietin-1 is stored in platelets
and maintains vascular integrity, and endothelium-derived angiopoietin-2 promotes vascular leakage. We determined
angiopoietin-1 and angiopoietin-2 levels in a cohort of children in Indonesia with DHF/DSS and related them to plasma
leakage markers. Patients with DHF/DSS had reduced angiopoietin-1 and increased angiopoietin-2 plasma levels on the
day of admission when compared with levels at discharge and in healthy controls. There was an inverse correlation
between angiopoietin-1 and markers of plasma leakage and a positive correlation between angiopoietin-2 and markers of
plasma leakage. Angiopoietin-1 levels followed the same trend as the soluble platelet activation marker P-selectin and
correlated with platelet counts. Dengue-associated thrombocytopenia and endothelial activation are associated with an
imbalance in angiopoietin-2: angiopoietin-1 plasma levels. This imbalance may contribute to the transient plasma
leakage in DHF/DSS.
INTRODUCTION
The clinical course of dengue virus infection ranges from
asymptomatic infection to severe disease, known as den-
gue hemorrhagic fever/dengue shock syndrome (DHF/DSS).
The latter is characterized by a transient endothelial hyper-
permeability, of which the pathogenesis is still incom-
pletely understood.1,2
Inflammatory cytokines and angiogenic proteins are impor-
tant mediators of vascular integrity.3 The angiogenic pro-
tein vascular endothelial growth factor (VEGF) is a strong
inducer of vascular permeability and several studies have
reported circulating VEGF levels in dengue patients with
contradicting results.4–8 However, the role of another class
of angiogenic proteins, known as angiopoietins, is unknown
in dengue.
Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) and
their endothelial tyrosine kinase receptor Tie-2 form a central
signaling system in endothelial permeability.9 Angiopoietin-
1–mediated Tie2 activation maintains the quiescent state of
the endothelium by stabilizing endothelial cell-cell junctions
and by countering the permeabilizing effects of VEGF.10
Angiopoietin-2 antagonizes the effects of Ang-1; it destabi-
lizes the endothelium by disrupting cell-cell adhesion and
primes the endothelial cells to the effects of pro-inflammatory
cytokines and VEGF.11 Angiopoietin-2 is almost exclusively
produced in endothelial cells and stored in Weibel-Palade
bodies (WPBs), from which it can be rapidly released upon
activation of the endothelium.12 Angiopoietin-1 is produced
in pericytes and smooth muscle cells, but platelets also contain
high quantities of Ang-1.13 Thus, the number and activation
status of circulating platelets may influence plasma Ang-1
levels. Evidence is increasing that platelets are important cells
for maintaining vascular stability and platelet-derived Ang-1
may be one of the factors involved.14
Dengue hemorrhagic fever/dengue shock syndrome is asso-
ciated with thrombocytopenia, inflammation, and endothelial
cell activation, and these processes might lead to significant
alterations in the balance between Ang-1 and Ang-2, favoring
plasma leakage and hemorrhage.15 We therefore studied
Ang-1 and Ang-2 levels children with DHF/DSS and related
these levels to markers of plasma leakage.
METHODS
This study was part of a larger cohort study that investi-
gated pathophysiologic mechanisms of severe dengue. Con-
secutive children with DHF/DSS £ 15 years of age who were
admitted to the pediatric ward or intensive care unit of the
Dr. Kariadi University Hospital in Semarang, Indonesia, dur-
ing 2005–2006 were enrolled in the study. Study details and
clinical characteristics have been reported.16 All patients had
positive results for dengue-specific IgM, as determined by
enzyme-linked immunosorbent assay (Focus Technologies,
Chanhassen, MN). The Ethics Committee of Diponegoro
University in Indonesia approved the study. Written informed
consent was obtained from the parents or legal guardians of
the children.
Forty-nine children, for whom sufficient blood sample vol-
ume was available, were randomly selected from this larger
cohort and classified as DHF or DSS according to World
Health Organization criteria.17 Twenty-five healthy children
from Indonesia served as controls. Demographic and clinical
characteristics of study participants are shown in Table 1.
Fluid resuscitation was performed in all patients according
to World Health Organization–based protocols. Blood was
drawn the days of enrollment and of discharge by using a
syringe and directly transferred to vacutainers containing
sodium citrate as an anticoagulant. Sodium citrate was used
because other anticoagulants or serum result in platelet activa-
tion and release of platelet-derived molecules such as Ang-1.
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Short application of a tourniquet for blood drawing was often
inevitable. Blood samples were processed as soon as possible
and handled with care to avoid in vitro platelet activation.
Blood was centrifuged for 20 minutes at 1,600 + g, and plasma
was stored at −80°C. Plasma levels of Ang-1, Ang-2, and
P-selectin were measured by using commercial enzyme-linked
immunosorbent assay kits (R&D Systems, Minneapolis, MN).
RESULTS
Patients with DHF/DSS had lower Ang-1 levels at enroll-
ment compared with corresponding discharge levels and
levels in controls, and had the lowest median level in children
with DSS (Figure 1A). Nineteen patients had an Ang-1 level
below the detection limit of 0.1 ng/mL at enrollment. In con-
trast, children with DHF/DSS had higher Ang-2 levels at
enrollment than at discharge and compared with healthy con-
trols (Figure 1B). Taken together, DHF/DSS was associated
with a clear increase in Ang-2/Ang-1 ratios, and those with
DSS had the highest ratios (Figure 1C). Five children died
and although their Ang-1 levels were in the lowest range,
their corresponding Ang-2 levels were more evenly distrib-
uted (Figure 1). There was no difference in Ang-1 and Ang-2
levels between children with and without bleeding.
The association of Ang-1 and Ang-2 levels with plasma
leakage was determined by using serum albumin level and
the pleural effusion index (PEI). This index was defined as
100 times the maximum width of the (right or left) pleural
effusion on a chest radiograph (right lateral decubitus posi-
tion) divided by the maximum width of the ipsilateral hemi-
thorax. The Ang-1 levels at enrollment correlated positively
with albumin levels (Spearman R [Rs] = 0.55, P < 0.0001)
and negatively with the PEI (Rs = −0.39, P = 0.005).
The Ang-2 levels correlated inversely with serum albumin
(Rs = −0.38; P = 0.009) but not with the PEI. The Ang-2:
Ang-1 ratio was related with the PEI (Rs = 0.43, P = 0.002)
and albumin levels (Rs = −0.60, P < 0.0001). The Ang-1 or
Ang-2 levels did not correlate significantly with hematocrit
values. Although platelet numbers correlated with serum
albumin levels (Rs = 0.44, P < 0.05), there was no significant
correlation with the PEI (Rs = −0.26, P = 0.07).
As mentioned, platelets contain high quantities of Ang-1
and release Ang-1 during platelet activation.13 The Ang-1
levels correlated with the platelet count (Rs = 0.44, P <
0.002). Plasma levels of platelet activation marker P-selectin
followed the trend of Ang-1 levels and showed a low median
level at admission (45.3 ng/mL; interquartile range = 29.4–
66.3 ng/mL) that had increased by the day of discharge (120.7
ng/mL; interquartile range = 91.6–187.5 ng/mL). Nonetheless,
Ang-1 levels only weakly correlated with P-selectin levels (Rs
= 0.30, P < 0.04) at enrollment, but when the 19 samples with
Ang-1 levels below the detection limit were not analyzed, this
correlation improved considerably (Rs = 0.69, P < 0.0001).
Figure 1. Plasma levels of (A) angiopoietin-1 and (B) angiopoietin-2 and corresponding angiopoietin-2:angiopoietin-1 ratios (C) in children in
Indonesia with dengue hemorrhagic fever (DHF) (n = 26) and dengue shock syndrome (DSS) (n = 23) on day 0 (day of admission), day of
discharge (n = 44) and in a control group of healthy children from Indonesia (n = 25). The minimum detection limit of angiopoietin-1 was 0.1 ng/mL.
Black points indicate non-survivors. Horizontal lines represent median values. P values were determined by Wilcoxon signed-rank test for data in
time and Mann-Whitney U test for comparison with the control group. *P < 0.05.
Table 1
Demographic and clinical characteristics of the patients studied*
Characteristic
DHF (DHF I and II),
n = 26 (53%)
DSS (DHF III and IV),
n = 23 (47%)
Male sex 12 (46) 7 (30)
Age, years 8 (6–10) 8 (6–10)
Body weight, kg 20 (17–28) 24 (18–30)
Body height, cm 125 (111–135) 120 (113–140)
Body temperature, °C 37.6 (37.0–38.4) 38.0 (37.0–38.5)
Duration of fever
until admission, days
4.0 (3.0–5.0) 4.0 (4.0–5.0)
Tourniquet test positive 17/23 (74) 10/16 (63)
Petechiae 1/17 (6) 1/15 (7)
Epistaxis 3 (12) 0 (0)
Gum bleeding 0 (0) 0 (0)
Hematemesis 2 (8) 0 (0)
Melena 0 (0) 1 (4)
Hemoglobin, g/dL 13.1 (12.7–14.0) 13.5 (12.3–14.2)
Hematocrit, % 38.0 (37.9–41.3) 40.0 (36.0–43.5)
Platelet count + 109/L 62 (39–88) 39 (26–68)
Leukocyte count,
+ 103 cells/mL
5.0 (3.1–7.8) 5.0 (3.0–9.5)
Albumin serum, g/dL, 3.3 (2.9–3.8) 2.8 (2.5–3.4)†
Alanine aminotransferase,
U/dL
48 (31–82) 46 (32–71)
Pleural effusion index 8 (0–22) 18 (11–28)†
*Values are medians (interquartile ranges) or absolute no. (%). All data are data at
enrollment, except for bleeding manifestations, which are presented for the whole duration
of admission. DHF = dengue hemorrhagic fever; DSS = dengue shock syndrome.
†P < 0.05, by Mann-Whitney U test.
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DISCUSSION
This study shows that DHF/DSS is associated with reduced
Ang-1 plasma levels and increased Ang-2 levels. These pro-
teins and their endothelial receptor are important mediators
of vascular integrity, and we speculate that this imbalance in
the Ang/Tie system contributes to the transient increase in
vascular permeability. Platelets contain Ang-1, and we hypoth-
esize that dengue-associated thrombocytopenia explains the
low Ang-1 levels. Increasing evidence suggests a role for plate-
lets in regulation of vascular integrity with Ang-1 and other
platelet-derived angiogenic proteins as central mediators.14 As
suggested by others, platelet count and activation status should
be taken into account when plasma levels of platelet-derived
proteins are measured.18,19
Angiopoietin-2 is produced in endothelial cells and stored
in WPBs.12 The finding of high levels of von Willebrand fac-
tor, the most abundant WPB constituent, in dengue patients,
supports the notion that endothelial cell activation with WPB
exocytosis is an important feature of dengue infection.15,20
Although the exact mechanisms of increased WPB exocytosis
with subsequent Ang-2 release in dengue are unknown, we
hypothesize that endothelial activation caused by increased
pro-inflammatory cytokines is centrally involved.21 In addi-
tion to the effect of inflammatory cytokines, other mecha-
nisms may also be involved, including direct interaction of
dengue virus with endothelial cells, release of mast cell prod-
ucts, and pro-coagulant factors such as thrombin.21–25
No definite conclusion on a causal relationship of Ang-1
and Ang-2 levels and plasma leakage could be made in this
observational study. Similar trends in Ang-1 and Ang-2 levels
have been found in severe malaria and sepsis,26,27 but in con-
trast to DHF/DSS and sepsis, plasma leakage is not a promi-
nent feature of malaria. Differences in other mediators of
vascular permeability, such as pro-inflammatory cytokines
and angiogenic proteins and their soluble receptors, might
account for these differences in vascular permeability.
Our study had some limitations. First, no values for the
platelet count at discharge and in the control group were
available. Second, despite our efforts to limit ex vivo platelet
activation, some degree of activation is often inevitable and
this should be taken into account when interpreting plasma
Ang-1 and P-selectin levels. Angiopoietin-1 levels across dif-
ferent studies seem to vary more than Ang-2 levels in con-
trols.16,28–31 Angiopoietin-1 levels in the controls of our study
were comparable with those of other studies, which also
found relatively higher Ang-1 levels.29,30 Therefore, we sug-
gest that relative changes in Ang-1 levels within one study
may be more informative than comparing absolute Ang-1
levels between studies. Third, the dengue diagnosis was based
on the presence of dengue-specific IgM in a single sample.
False-positive IgM results caused by cross-reactivity may
occur in patients with infectious diseases other than dengue,
although the fact that all children in our study population had
proven plasma leakage (pleural effusion on chest radiograph)
around defervescence, a finding specific for dengue, makes
alternative diagnoses unlikely.
In conclusion, DHF/DSS is associated with an imbalance in
the Ang/Tie system favoring plasma leakage. Dengue-associated
thrombocytopenia may play a so far overlooked role in the
transient plasma leakage seen in DHF/DSS. No specific treat-
ment for dengue is available. Interventions aimed at the
prevention of thrombocytopenia or the correction of the
imbalance in the Ang/Tie system might offer a valuable
adjunctive treatment of this devastating disease.
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